Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
UCB
Biotech
UCB enters TCE space with $1.1B deal for autoimmune candidate
UCB has entered the red-hot T-cell engager space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.
James Waldron
Mar 4, 2026 8:20am
Fierce Pharma
FDA's response letter salvo sheds light on drug refusal process
Jul 11, 2025 10:15am
UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2
Dec 16, 2024 3:19pm
UCB's tau drug flunks Alzheimer's trial days after Roche's exit
Nov 1, 2024 6:01am
Roche tosses out $120M tau prospect, returning rights to UCB
Oct 22, 2024 8:30am
Biogen, UCB report phase 3 lupus win after failing earlier trial
Sep 24, 2024 6:00am
